Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Thoratec's HeartMate II Implant Boosts Stroke-Free Survival Four-Fold - Study

This article was originally published in The Gray Sheet

Executive Summary

Thoratec's next-generation HeartMate II continuous-flow left ventricular assist device enables a more than four-fold increase in two-year survival rate free from stroke and reoperation compared with the firm's HeartMate XVE pulsatile-flow LVAD, according to study data unveiled Nov. 17

You may also be interested in...



Thoratec Adds Sales Reps For Launch Of HeartMate II As Destination Therapy

Thoratec is beefing up its sales force to emphasize physician referrals now that FDA has approved its HeartMate II ventricular assist device as a "destination" therapy for patients who are not candidates for a heart transplant

Thoratec Adds Sales Reps For Launch Of HeartMate II As Destination Therapy

Thoratec is beefing up its sales force to emphasize physician referrals now that FDA has approved its HeartMate II ventricular assist device as a "destination" therapy for patients who are not candidates for a heart transplant

Thoratec-HeartWare LVAD Deal Is Dead Following FTC Challenge

Thoratec abandoned its planned $282 million acquisition of ventricular-assist-device-maker HeartWare July 31 after the deal was challenged by the Federal Trade Commission

Related Content

Topics

UsernamePublicRestriction

Register

MT028207

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel